Real-world healthcare resource utilization in patients with indolent non-Hodgkin lymphoma: differences between patients treated with first-line ibrutinib or bendamustine + rituximab.

Conclusions: These real-world findings highlight the importance of considering the healthcare resource utilization and the associated costs of iNHL patients which may be associated with their first-line therapy. PMID: 31910684 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31910684?dopt=Abstract

Source: Current Medical Research and Opinion - January 9, 2020 Category: Research Tags: Curr Med Res Opin Source Type: research